Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. - Wikidata - awgldk - TriplyDB

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

http://www.wikidata.org/entity/Q43488190

about

Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety Histoplasmosis: a clinical and laboratory update Dendritic cell interactions with Histoplasma and Paracoccidioides Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009 Apoptosis modulates protective immunity to the pathogenic fungus Histoplasma capsulatum Clinical use of anti-TNF therapy and increased risk of infections Granulomatous hepatitis secondary to histoplasma infection after treatment with infliximab.T cells require tumor necrosis factor-alpha to provide protective immunity in mice infected with Histoplasma capsulatum.Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept.Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease.Role of tumour necrosis factor (TNF) in host defence against tuberculosis: implications for immunotherapies targeting TNF The role of cytokines and chemokines in Histoplasma capsulatum infection.Histoplasma mechanisms of pathogenesis--one portfolio doesn't fit all.Tuberculosis, lung infections, interstitial lung disease, social issues and journalology in AJRCCM 2003.CCR5 deficiency mitigates the deleterious effects of tumor necrosis factor α antagonism in murine histoplasmosis Etanercept: a clinical review of current and emerging indications.Gastrointestinal histoplasmosis.Inflammation--a new therapeutic target in pneumonia.Immunosuppression related to collagen-vascular disease or its treatment.TNFalpha blockade in human diseases: mechanisms and future directions.Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases TNF-alpha antagonism generates a population of antigen-specific CD4+CD25+ T cells that inhibit protective immunity in murine histoplasmosis.The Histoplasma capsulatum vacuolar ATPase is required for iron homeostasis, intracellular replication in macrophages and virulence in a murine model of histoplasmosis Pulmonary complications of tumor necrosis factor-targeted therapy.Characterization of the Histoplasma capsulatum-induced granuloma.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.Etanercept: efficacy and safety for approved indications.Assessing the safety of biologic agents in patients with rheumatoid arthritis.Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy.Infection risk associated with anti-TNF-α agents: a review.Systematic review: Whipple's disease (Tropheryma whipplei infection) and its unmasking by tumour necrosis factor inhibitors.Cutaneous histoplasmosis as a complication after anti-TNF use--Case report.SCEDOSPORIUM INFECTION IN A PATIENT WITH ANTI-TNFα THERAPY.Methylxanthine inhibit fungal chitinases and exhibit antifungal activity.Fatal staphylococcal sepsis in Crohn's disease after infliximab.

P2860

Q24604509-A438B89E-4CB5-4E77-B487-5A488B4B7A34 Q24673716-2A2A5488-CBA6-4319-8A9F-B05D1D1CAB80 Q24675642-06713E67-994F-4E8A-BFDF-096EAF9D11BC Q27003889-C436E224-5FAF-4833-A6E1-712D39654F82 Q29302324-6302B429-CFBA-43B1-A758-8EEDB63728D3 Q33556794-8F191B2C-80D0-4D28-BB1B-34BEEE364E48 Q33819684-DEA2BBDA-391D-491D-A776-BF1F1C2274B9 Q33909467-C76BCB4E-410B-44AE-B6B2-96AEAFB676E9 Q33942647-15687371-8FD7-44FB-8FF7-108E136DEA51 Q34338096-A3035670-39B5-4A4A-BEE2-E2A50B84B402 Q34399044-E7EDE976-F8C8-416D-83BA-18A580C1A203 Q34427249-4B4B3D87-E2C7-4A7F-B523-B249B7A2BF41 Q34607722-7647FA1B-F4B5-4E3D-9C17-CB1955F50417 Q35182119-8A8B7CCF-3C3D-4943-9A1D-D21684BE7D13 Q35553478-B268C60E-8FC2-4C0E-893F-3509E34AACD2 Q35583253-BA286B3D-4FCC-4653-B99E-AF3EB6C815CF Q35585157-BE552763-5A1B-4538-A3B0-E032680ADE0E Q35626620-F423631C-73B4-45C2-8602-8663EDBF610E Q35766007-FE9F5E5D-272F-4BB6-AA30-133712D88292 Q35779227-DA8927C5-FF85-4416-82F1-807833912071 Q36011779-B64242C6-A51B-4437-AE51-DA3CC1D4B979 Q36095647-3FC3E6C9-D106-48FE-BA9A-27A99AE31110 Q36328708-A02C69A1-87A6-4873-BDE3-DFEF310428CC Q36536886-2AB08D7B-9BC0-49DE-AF6E-98799BEF0EF7 Q36699795-FE8A28BB-C01E-4B33-8BC7-D9D224744D45 Q36749486-382E41C6-0772-4CDA-9387-74870983C1A3 Q36944562-E869ADC1-83C5-4FEE-8C3E-D3A30A9C8414 Q37345155-E8181F18-6A44-44AB-B0CC-8740B05B6483 Q37357512-87DC7921-1CA2-4DE7-B563-35AE6D521212 Q37814549-7D003ABD-AAC0-4561-AA9E-B59B7CF319DE Q37918330-DFC44CE8-383E-4FDB-812E-5CCF0CD58200 Q37954714-D1B9B551-DF64-46EF-B6E8-2112D113BB75 Q38020463-E9E69BAB-79DC-4035-ABC5-027B930AECC0 Q38108468-EAAB2923-DC86-4AE7-89AF-C7551C3DDB98 Q38335718-94CAFE38-1C67-45D0-8ED8-3DFF5CE3C9F0 Q38360672-F31066C0-CDB8-4E47-A367-07F98725D02C Q41030645-55ED265B-38C2-4354-8DB3-F1E7534B4FED Q42727727-4FBA28F4-45B7-47A3-987C-1EEE2CE92A3F Q42940125-9C1D098E-91C1-4149-8641-14088D6ECCFE Q47915123-B33B0C23-CAB0-412D-A9B3-F34A22AB1483

P2860

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

http://www.wikidata.org/entity/Q43488190

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@en

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@nl

type

label

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@en

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@nl

prefLabel

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@en

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@nl

P1433

Q43488190-0166B39E-7923-4B7E-BCD7-5238B4664331

P1476

Q43488190-E6D2D0BF-C657-4026-A897-63A1222C5876

P2093

Q43488190-3BBFAA0C-9F84-458C-97D1-A9D6D0CA25E5

Q43488190-3F5633BD-3C6F-43CB-9B19-8997DCC5D498

Q43488190-943F6A12-E646-4554-AFFE-511C754C969B

Q43488190-C3C503CA-A519-45AC-BEED-FB0D36F9B07E

Q43488190-C40E6164-EE05-4BA0-A6A5-3CAE13E0CF3E

Q43488190-DA02414B-3414-4ED5-A43B-E757DA14092C

Q43488190-F733AB42-CD2E-43AA-9A70-66583F0621BD

P2860

Q43488190-02D08110-F838-4BE2-845D-50B334B185D6

Q43488190-0516D793-5533-4E18-B0C5-A994BB40B384

Q43488190-07C24E85-D8CC-4AB7-AD5F-CC1899B97F32

Q43488190-17140276-D36C-4F63-A331-023FF90293C6

Q43488190-27A30FE8-E72D-4674-92E2-83E87D1764DD

Q43488190-39A6AF0B-2739-4FEF-A3F1-6B4BB8881F3B

Q43488190-43354572-81A8-4093-88F0-F75E9D7E6BFC

Q43488190-6580DDA8-1078-4E6A-9ACC-3FF35CB6391B

Q43488190-76E5FB47-C9AC-4211-B8CF-9DA7B3DD25AE

Q43488190-79D39122-16A2-4F5B-87C9-A977D14E7875

P304

Q43488190-BC5DDF03-6A7B-4E64-B4C7-141F834BFD2F

P31

Q43488190-30D911DC-A663-4327-A53E-9820A5C96F9A

P356

Q43488190-DDD884FE-CEE6-4426-B7E5-8F8931F846A1

P407

Q43488190-1A609599-A16C-4FAE-B3E6-2C92EEFCBBD1

P433

Q43488190-0FDB827E-8FFB-447E-A4E2-3767B72A3729

P478

Q43488190-25555EA3-A269-4C0A-9069-B7F60E4126C2

P50

Q43488190-9D8EBE74-C855-4363-A98B-59183350130B

P577

Q43488190-DAC0FC7B-9B9D-4919-9487-BD31AC9E2505

P698

Q43488190-6B4C6182-E677-4E1C-A52D-0D57DAAEB842

P356

RCCM.200206-563OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy.

@en

P2093

Aruna Sannuti

http://www.w3.org/2001/XMLSchema#string

Chadi A Hage

http://www.w3.org/2001/XMLSchema#string

Homer L Twigg

http://www.w3.org/2001/XMLSchema#string

Karen L Wood

http://www.w3.org/2001/XMLSchema#string

Kenneth S Knox

http://www.w3.org/2001/XMLSchema#string

Martin B Kleiman

http://www.w3.org/2001/XMLSchema#string

Richard B Day

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

TNF-alpha and IL-12: a balancing act in macrophage functioning.

Cell-mediated immunity to Histoplasma capsulatum.

The epidemiology of histoplasmosis: a review.

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area.

Histoplasmosis in immunosuppressed patients.

Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens.

Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

P304

1279-1282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200206-563OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

167

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12615627

http://www.w3.org/2001/XMLSchema#string